{"filings":[{"id":1940642,"accession_number":"0001127537-26-000035","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2026-07-29T20:07:39+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmonx Q2 revenue $22.8M (-5% YoY); net loss narrows to $10.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $22.8M, down 5% YoY; U.S. $14.2M (-4%), international $8.6M (-6%; ex-China +12%).","Record gross margin 78% (vs 72% YoY); operating expenses down 16% to $26.8M.","Net loss $10.1M ($0.24/share) vs $15.2M loss; adjusted EBITDA loss $5.1M, down 39%.","Cash $55.8M; FY2026 guidance: revenue $90-92M, gross margin ~76%, opex $109-111M.","Management cites cost realignment and expects return to year-over-year revenue growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":860837,"accession_number":"0001127537-26-000031","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2026-06-04T20:04:20+00:00","items":["5.07"],"status":"ready","headline":"Pulmonx shareholders elect three Class III directors, ratify auditor, approve say-on-pay at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Three Class III directors elected: Thomas W. Burns (19.75M for), Georgia Garinois-Melenikiotou (17.68M for), Dana G. Mead, Jr. (19.85M for); broker non-votes 11.83M each.","Ratification of BDO USA as auditor for FY2026 passed with 31.46M for, 0.10M against, 1.09M abstain.","Non-binding advisory vote on executive compensation approved: 17.20M for, 3.49M against, 0.13M abstain, 11.83M broker non-votes.","Annual Meeting turnout: 32,645,270 shares voted, representing 77.29% of outstanding stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91452,"accession_number":"0001127537-26-000020","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmonx Q1 revenue falls 9% YoY to $20.6M; net loss $13.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue $20.6M (-9% YoY, -12% constant currency); U.S. $13.3M (-7%), international $7.3M (-12%).","Ex-China international revenue grew 22% YoY; China sales paused awaiting registration renewal.","Gross margin improved to 78% (vs 73% Q1 2025); total op. expenses $29.0M (-6% YoY).","Adjusted EBITDA loss $8.5M; net loss $13.7M ($0.33 per share) vs $14.4M ($0.36) a year ago.","FY 2026 outlook reaffirmed: revenue $90-92M, gross margin ~75%, opex $113-115M, cash burn ~$23M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":20586000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101535,"accession_number":"0001193125-26-092064","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["1.01","1.02","2.03","3.02","9.01"],"status":"ready","headline":"Pulmonx enters $60M secured credit facility with Perceptive; draws $40M upfront","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$60M senior secured term loan from Perceptive; $40M drawn at closing, up to $20M additional tranches tied to $92.5M and $100M revenue milestones.","Interest rate: SOFR + 7.00% margin (minimum SOFR floor 3.75%); up to 2% margin can be paid-in-kind for 36 months.","Issued warrants to Perceptive for 1M shares at $1.92 (25% premium to 10-day VWAP); additional warrants on delayed draw fundings.","Maturity March 2, 2031; prepayment premium of 2-10% if within first 4 years; exit fee of 1.5%; minimum liquidity covenant of $4M.","Repaid and terminated existing CIBC credit agreement; no termination fees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101534,"accession_number":"0001127537-26-000003","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmonx Q4 revenue declines 5% YoY; full year up 8%; guides flat FY2026 revenue $90-92M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $22.6M, down 5% YoY (down 7% constant currency); US revenue fell 11% to $14.1M.","Full year 2025 revenue $90.5M, up 8% YoY (7% constant currency); international revenue up 23% to $33.5M.","Net loss improved: Q4 net loss $10.4M ($0.25/sh) vs $13.2M ($0.33/sh); full year loss $54.0M vs $56.4M.","Secured up to $60M in new 5-year interest-only credit facility extending debt maturity to 2031; cash $69.8M at year end.","FY2026 guidance: revenue $90-92M (roughly flat); gross margin ~75%; operating expenses $113-115M; cash burn ~$23M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117878,"accession_number":"0001127537-25-000058","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmonx Q3 rev $21.5M (+5%), net loss $14.0M; guides FY rev $89-90M; adds COO role","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue $21.5M (+5% YoY); US $14.0M (+1%), Intl $7.5M (+15%).","Gross margin 75% vs 74% YoY; net loss $14.0M ($0.34/share) vs $14.1M ($0.36) YoY.","Adjusted EBITDA loss $8.2M vs $8.1M YoY; cash $76.5M.","FY2025 revenue guidance narrowed to $89-90M; operating expenses $125-126M incl ~$21M SBC.","Glen French reappointed CEO; Derrick Sung appointed COO & CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":67899000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117877,"accession_number":"0001127537-25-000052","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Pulmonx reappoints Glen French as CEO and Derrick Sung as COO/CFO; Q3 preliminary revenue ~$21.5M","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Glen French (former CEO 2014-2024) reappointed President and CEO; Derrick Sung (former CFO) appointed COO and CFO effective Nov 3, 2025.","Steve Williamson and Mehul Joshi resigned as CEO and CFO; each will serve as advisors through Dec 1, 2025; departures not due to any disagreement.","Preliminary Q3 2025 revenue expected approximately $21.5M; full results and earnings call rescheduled to Nov 12, 2025.","Williamson receives $600K severance plus COBRA; Joshi receives $347,625 plus COBRA as separation compensation.","French receives $625K base salary, 100% target bonus, RSU for 1.2M shares, and PSU for 800K shares with $4.00 stock price performance condition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134332,"accession_number":"0001127537-25-000041","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmonx Q2 revenue up 15% to $23.9M but cuts FY2025 guidance to $90-92M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $23.9M (+15% YoY); U.S. $14.7M (+6%), International $9.1M (+32% constant currency +27%).","Net loss $15.2M ($0.38/sh) vs $15.3M ($0.39/sh) prior year; Adjusted EBITDA loss $8.4M vs $7.6M.","Full-year 2025 revenue guidance cut to $90-92M from $96-98M; OpEx lowered to $128-130M from $133-135M.","Gross margin 72% vs 74% prior year; cash, cash equivalents & marketable securities $84.2M.","Added 12 new Zephyr Valve U.S. treatment centers, trained 26 physicians; over 20k first-time patient engagements."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":46397000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151144,"accession_number":"0001127537-25-000028","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pulmonx stockholders reelect three directors; say-on-pay passes by slim margin","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All three Class II nominees elected: Ferrari (16.97M for, 11.95M withheld), Florin, Williamson.","Say-on-pay approved with 14.71M for vs 14.20M against (50.9% support); 4.40M broker non-votes.","Ratification of BDO USA as auditor received 33.03M for, 0.28M against.","About 82.8% of outstanding shares (33.3M of 40.2M) were represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151143,"accession_number":"0001127537-25-000023","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmonx Q1 2025 revenue $22.5M (+20% YoY); net loss $14.4M; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue of $22.5M, up 20% YoY (21% constant currency); U.S. $14.2M (+11%), international $8.3M (+39%).","Net loss $14.4M ($0.36 per share) vs $13.7M ($0.36) in Q1 2024; adjusted EBITDA loss $8.5M vs $8.0M.","Reaffirms FY2025 revenue guidance $96M-$98M; expects gross margin ~74% and OpEx $133M-$135M.","U.S. DOJ declined to intervene in case against Pulmonx and closed the civil investigative demand.","Amended CIBC loan to extend interest-only period through October 2027; cash & securities $88.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":22538000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170035,"accession_number":"0001127537-25-000003","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmonx reports record Q4 revenue $23.8M (+23% YoY) and FY2024 revenue $83.8M (+22%); FY2025 guidance $96-98M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q4 2024 worldwide revenue $23.8M, up 23% YoY; U.S. revenue $15.9M (+16%), international $7.9M (+42%).","Full year 2024 revenue $83.8M, up 22% YoY; net loss $56.4M ($1.44/shr) narrowed from $60.8M ($1.60/shr) in 2023.","Adjusted EBITDA loss improved to $31.3M in 2024 from $39.0M in 2023; gross margin stable at 74%.","Cash and equivalents $101.5M at year-end 2024; added 11 new U.S. Zephyr Valve treatment centers in Q4.","FY2025 revenue guidance $96-98M (15-17% growth); operating expenses $133-135M including $22M stock comp."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":83789000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187055,"accession_number":"0001127537-24-000082","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmonx Q3 2024 revenue $20.4M (+15% YoY), net loss $14.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue $20.4M, up 15% YoY; U.S. revenue $13.8M (+17% YoY); international $6.6M (+12%).","Gross margin 74% unchanged YoY; net loss $14.1M ($0.36 loss per share) vs $14.9M ($0.39) in Q3 2023.","Adjusted EBITDA loss $8.1M vs $9.0M in Q3 2023; cash & marketable securities $107.8M as of Sep 30.","Full-year 2024 revenue guidance reaffirmed $81M-$84M; op ex guidance narrowed to $122M-$124M.","Added 15 new Zephyr Valve U.S. treatment centers; AeriSeal CONVERT trial showed 77.6% conversion rate."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":60024000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203585,"accession_number":"0001127537-24-000073","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmonx reports record Q2 revenue $20.8M (+21% YoY); net loss narrows to $15.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue $20.8M, up 21% YoY; U.S. revenue $13.9M (+26%); International $6.9M (+12%).","Net loss $15.3M ($0.39/share) vs $16.2M ($0.43) in Q2 2023; adjusted EBITDA loss $7.6M vs $10.3M.","Gross margin held at 74%; operating expenses $30.9M, including $1.7M one-time software impairment.","Added 17 new U.S. Zephyr Valve treatment centers; first U.S. patients treated in AeriSeal CONVERT II trial.","Full-year 2024 guidance reaffirmed: revenue $81-84M, gross margin 74-75%, opex $127-129M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":39637000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220079,"accession_number":"0001127537-24-000063","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Pulmonx extends and expands headquarters lease through 2035, adds 25,254 sq ft","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Extended lease for 24,591 sq ft at 700 Chesapeake Dr to July 31, 2035; monthly base rent starts at $113,118.60 Aug 2025.","Will add 25,254 sq ft at 200 Chesapeake Dr effective June 1, 2028; monthly rent starts at $107,329.50 with 3.5% annual escalations.","Sublease for Expansion Premises with Genomic Health runs through May 31, 2028; then direct lease with Landlord begins.","Two five-year extension options granted for the combined 49,845 sq ft premises.","Four-month rent abatement on Existing Premises (Aug–Nov 2025) valued at $452,474.40."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220078,"accession_number":"0001127537-24-000057","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pulmonx annual meeting elects directors; say-on-pay passes with narrow margin","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Glendon E. French re-elected with 16.9M for vs 13.7M withheld; Tiffany Sullivan with 16.7M for vs 13.9M withheld.","Ratification of BDO USA as auditor approved: 34.3M for, 38.9K against.","Non-binding advisory vote on executive compensation approved: 16.3M for, 14.3M against, 3.8M broker non-votes.","Broker non-votes of 3.8M shares present on director election and say-on-pay proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220077,"accession_number":"0001127537-24-000045","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmonx Q1 revenue $18.9M (+30% YoY); net loss narrows to $13.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $18.9M, up 30% YoY (29% constant currency); U.S. revenue $12.9M (+38%).","Net loss $13.7M ($0.36 per share) versus $15.9M ($0.42) in Q1 2023; Adjusted EBITDA loss $8M vs $11.2M.","Gross margin 75% (vs 73% YoY); FY 2024 revenue guidance reaffirmed $81M-$84M; operating expenses guidance tightened to $127M-$129M.","Cash and equivalents $120.4M; clinical milestones: first AeriSeal CONVERT II patient and first Japanese Zephyr post-approval patient."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":18854000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220076,"accession_number":"0001127537-24-000039","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Pulmonx appoints Mehul Joshi as CFO effective April 3, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mehul Joshi named CFO; previously CFO of PhenomeX and senior finance roles at ResMed and Gilead.","Annual base salary $450K; target bonus 50% of base; sign-on bonus $200K with clawback provisions.","Initial equity grants: non-statutory stock option valued at $1.375M and RSU valued at $1.35M, both vesting over 4 years.","John McKune, interim CFO since Oct 2023, returns to VP Finance and Corporate Controller.","Severance and change-in-control benefits: 12 months salary plus bonus acceleration upon qualifying termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239813,"accession_number":"0001127537-24-000013","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmonx Q4 revenue $19.3M (+25% YoY); full-year 2023 revenue $68.7M (+28% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q4 U.S. revenue of $13.7M (+45% YoY); added 14 new Zephyr Valve treatment centers.","Gross margin improved to 75% in Q4; full-year gross margin flat at 74%.","Net loss of $13.9M ($0.36/share) in Q4; full-year net loss $60.8M ($1.60/share).","Adjusted EBITDA loss narrowed to $39.0M in 2023 from $41.1M in 2022.","2024 revenue guidance of $81-84M; expects gross margin 74-75% and OpEx $132-134M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":68675000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239812,"accession_number":"0001127537-24-000012","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Pulmonx CEO Glen French retires; Steve Williamson appointed President and CEO effective March 15, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Glen French resigns as CEO effective March 15; will serve as Senior Advisor until May 1, then remain on Board.","Steve Williamson named CEO and Board member; previously Chief Commercial Officer at Outset Medical.","Williamson receives $580k base salary, 75% target bonus, and equity grants totaling $5M (option + RSU).","Board reduces size to eight directors after Alissa Hsu Lynch declines re-election at 2024 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257314,"accession_number":"0001127537-23-000042","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2023-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmonx Q3 revenue $17.7M record +31% YoY; raises FY2023 guidance to $67-68M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record worldwide revenue $17.7M (+31% YoY); U.S. revenue $11.8M (+41% YoY).","Net loss $14.9M ($0.39 EPS) vs $14.2M ($0.38 EPS) in Q3 2022.","Raised 2023 revenue guidance to $67-68M (prior $64-66M); gross margin ~74%.","Adjusted EBITDA loss improved to $9.0M from $9.7M YoY.","Japan MHLW approved Zephyr Valve reimbursement for severe COPD/emphysema."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":49397000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257313,"accession_number":"0001193125-23-253468","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2023-10-10T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Pulmonx CFO Sung resigns; McKune interim CFO; Q3 revenue prelim ~$17.6M (+30% YoY)","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Derrick Sung resigned effective Oct 10, 2023 to pursue other opportunity; no disagreement with company.","John McKune (VP, Corp Controller) appointed Interim CFO; receives $75k cash bonus and $75k RSU grant.","Preliminary Q3 2023 revenue ~$17.6M, up ~30% YoY, a record quarter.","Search for permanent CFO initiated; Sung remains advisory through Oct 31, then consulting through Mar 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274659,"accession_number":"0001127537-23-000032","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmonx Q2 revenue $17.2M (+23% YoY), raises FY2023 guidance to $64-66M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record worldwide revenue $17.2M, up 23% YoY; US revenue $11.0M up 28% YoY.","Gross margin 74% (vs 75% prior year); net loss $16.2M ($0.43/share).","Raised 2023 revenue guidance to $64-66M (from $63-65M); operating expenses maintained at $112-114M.","Added 15 new US Zephyr Valve treatment centers in Q2."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":31729000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291959,"accession_number":"0001127537-23-000023","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2023-05-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pulmonx stockholders reject non-binding advisory vote on executive compensation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Say-on-pay proposal failed: 13,654,112 for, 15,975,796 against, 2,987 abstain.","All three Class III director nominees elected: Thomas W. Burns, Georgia Garinois-Melenikiotou, Dana G. Meade, Jr.","Ratification of BDO USA as auditor passed overwhelmingly: 32,890,592 for, 28,763 against.","Meeting had 32,920,550 shares present (~87.25% of outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.15,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291958,"accession_number":"0001127537-23-000014","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2023-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmonx Q1 revenue $14.5M (+35% YoY); reaffirms FY 2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue $14.5M, up 35% YoY; U.S. revenue $9.3M (+55% YoY).","Gross margin 73% vs. 75% in Q1 2022; net loss $15.9M ($0.42 per share).","Adjusted EBITDA loss $11.2M vs. $11.8M in prior-year period.","Added 15 new U.S. Zephyr Valve treatment centers in Q1 2023.","Full-year 2023 guidance reaffirmed: revenue $63-65M; gross margin 73-74%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":14535000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312711,"accession_number":"0001127537-23-000005","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2023-02-22T23:59:59+00:00","items":["2.02","2.03","9.01"],"status":"ready","headline":"Pulmonx Q4 revenue $15.4M (+13% YoY); draws $20M debt; FY23 guidance $63-65M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 revenue $15.4M, up 13% YoY; U.S. revenue $9.5M (+30% YoY).","Full year 2022 revenue $53.7M, up 11% YoY; net loss $58.9M ($1.59/share).","FY2023 revenue guidance $63-65M; gross margin 73-74%; operating expenses $112-114M.","Drew $20M from CIBC loan on Feb 21, 2023; floating rate at Prime +1%.","Added 17 new U.S. treatment centers in Q4, total 278; preparing for Japan launch."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":53662000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331222,"accession_number":"0001127537-22-000048","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"Pulmonx Q3 revenue $13.5M, cuts FY guidance to $51.5-52.5M; extends credit line to 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $13.5M (+2% YoY, +7% constant currency); US $8.4M (+22%), intl $5.1M (-20%).","Net loss $14.2M ($0.38/sh) vs $10.2M ($0.28) in Q3 2021; gross margin 75% vs 73%.","FY2022 revenue guidance cut to $51.5-52.5M from $55-60M; opex guidance lowered to $98-100M.","Extended loan with CIBC: maturity to Oct 2027, new $20M tranche, 24-month interest-only period.","Japan MHLW agreed to approve Zephyr Valves; AeriSeal data may expand treatable patient pool."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":38237000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348777,"accession_number":"0001127537-22-000033","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2022-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmonx Q2 revenue $14.0M (+14% YoY); net loss $14.6M; reaffirms FY outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $14.0M, up 14% YoY (19% constant currency); U.S. revenue $8.6M (+31%).","Net loss $14.6M ($0.40/share) vs $13.0M ($0.36/share) in Q2 2021.","Gross margin improved to 75% from 74% due to production efficiencies.","Added 18 new U.S. treatment centers (total 248); cash $166.8M.","FY2022 revenue guidance reaffirmed $55M-$60M; operating expenses $100M-$105M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":24735000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365564,"accession_number":"0001127537-22-000029","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2022-05-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pulmonx shareholders elect two Class II directors, ratify BDO USA, approve say on pay on annual basis","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Richard M. Ferrari and Daniel P. Florin as Class II directors with ~84% of votes cast.","Ratified BDO USA as independent auditor for FY2022: 34,070,598 for, 22,582 against, 131,873 abstain.","Approved executive compensation on non-binding advisory basis: 27,491,973 for, 3,963,314 against.","Approved holding future say-on-pay votes every year; next frequency vote by 2028 Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365563,"accession_number":"0001127537-22-000015","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2022-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmonx Q1 revenue $10.8M (+17% YoY); net loss $15.8M; reaffirms FY 2022 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue $10.8M, up 17% YoY (20% constant currency); US revenue $6.0M (+40%).","Net loss $15.8M ($0.43/share) vs. $12.5M loss ($0.35/share) in Q1 2021.","Gross margin improved to 75% from 72% YoY, driven by production efficiencies.","Added 16 new US Zephyr Valve treatment centers; total 230 centers.","FY 2022 outlook unchanged: revenue $55-60M; operating expenses $100-105M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":10785000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385114,"accession_number":"0001127537-22-000009","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K/A","filed_at":"2022-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmonx Q4 revenue $13.7M (+39% YoY); FY2022 guidance $55M-$60M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 revenue $13.7M, up 39% YoY; FY2021 revenue $48.4M, up 48% YoY.","Gross margin improved to 74.8% in Q4 and 73.6% for FY2021, vs 72.0% and 64.8% a year ago.","Net loss Q4 $13.0M ($0.35/sh); FY net loss $48.7M ($1.35/sh).","FY2022 revenue guidance $55M-$60M; Q1 2022 guidance $9M-$10M, reflecting COVID impact.","U.S. treatment centers for Zephyr Valves expanded to 214, up 45% from start of 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":48416000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385115,"accession_number":"0001127537-22-000003","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2022-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmonx Q4 revenue $13.7M (+39% YoY); FY rev $48.4M (+48%); guides FY22 $55-60M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $13.0M ($0.35/sh) vs $9.3M ($0.27/sh) YoY; FY net loss $48.7M ($1.35/sh) vs $32.2M ($3.16/sh).","Q4 gross margin 74.8% (vs 72.0% YoY); FY gross margin 73.6% (vs 64.8%); improvement from production efficiencies.","U.S. treatment centers for Zephyr Valves expanded to 214, a 45% increase since start of 2021.","FY 2022 revenue guidance $55-60M; Q1 2022 revenue expected $9-10M due to COVID impact.","Regulatory submission for Zephyr Valve approval in Japan made in December 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":48416000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402994,"accession_number":"0001127537-21-000045","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2021-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmonx Q3 revenue $13.3M (+25% YoY); net loss $10.2M; maintains FY guidance $49-51M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue $13.3M, up 25% YoY ($10.6M Q3 2020); U.S. revenue $6.9M (+28%), international $6.4M (+22%).","Gross margin improved to 73% (70% prior year); net loss $10.2M ($0.28 loss per share) vs $3.9M ($1.37 loss per share).","Added 18 new U.S. Zephyr Valve treating centers (total 198); positive coverage decisions from Anthem, BCBS Michigan, Horizon NJ (~44M covered lives).","Cash, cash equivalents, and marketable securities totaled $202.6M as of September 30, 2021.","Maintains FY 2021 revenue guidance $49-51M; expects near low end due to COVID headwinds; operating expenses guided $83-85M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":34708000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":421918,"accession_number":"0001127537-21-000037","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2021-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmonx Q2 2021 revenue $12.2M (+232% YoY); raises FY guidance to $49-51M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue $12.2M, up 232% YoY; U.S. revenue $6.6M (+343%), international $5.6M (+157%).","Gross margin 74% vs 28% a year ago; net loss $12.4M ($0.34 per share) vs $11.9M ($6.15).","Added 20 new U.S. Zephyr Valve treating centers (total 180); launched Chartis software upgrade.","FY 2021 revenue guidance raised to $49-51M from $48-50M; OpEx unchanged at $85-90M.","Cash and marketable securities $211.5M as of June 30, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":21447000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":421917,"accession_number":"0001127537-21-000033","cik":1127537,"company_name":"Pulmonx Corp","ticker":"LUNG","form_type":"8-K","filed_at":"2021-08-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pulmonx appoints Alissa Hsu Lynch and Tiffany Sullivan as Class I directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointments effective July 29, 2021; directors serve until 2024 annual meeting.","Lynch joins Audit Committee; Sullivan joins Nominating and Corporate Governance Committee.","Each receives $40k annual cash fee, initial RSU grant of $180k vesting over 3 years, plus annual equity grants.","Each enters standard indemnification agreement with Pulmonx."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":65045292.90445859,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}